CompletedNot Applicable

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

United States1,330 participantsStarted 2023-05-01

Plain-language summary

The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for the target population? Participants will receive genetic testing and counseling that may initiate life-saving screenings.

Who can participate

Age range25 Years – 100 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with serous ovarian cancer diagnosed more than two years prior to study contact
✓. Patients with breast cancer diagnosed at \<50 years of age more than two years prior to study contact
✓. Patients with triple negative breast cancer diagnosed more than two years prior to study contact
✓. Unaffected individuals reporting a family history of ovarian cancer
✓. Unaffected individuals reporting a family history of male breast cancer
✓. Unaffected individuals reporting a family history of breast cancer \<50 years

What they're measuring

Number of Genetic Counseling Appointments Completed Following MPM Delivery

Timeframe: Within six months of MPM delivery

Number of Genetic Counseling Appointments Completed Following Provider Nudge

Timeframe: Within six months of provider nudge

Trial details

NCT IDNCT05721326

SponsorAbramson Cancer Center at Penn Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Genetic Predisposition to Disease trials